Rapport Therapeutics, Inc.
RAPPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Rapport Therapeutics, Inc. focuses on Biotechnology services and products. Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering. At a $2.20B market cap, Rapport Therapeutics, Inc. ranks as a mid-cap company within healthcare. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Market Cap
$2.20B
Beta
1.03
P/E (TTM)
—
P/E (Fwd)
-8.75
EPS (TTM)
$-3.03
EPS (Fwd)
$-5.23
ROE
-40.0%
ROA
-25.8%
Cash
$436.1M
Total Debt
$10.1M
Free CF
-$56.0M
52W Change
63.3%
Annual Financials
Cash vs Debt
Where RAPP stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RAPP finished 32.78% above its 150-day moving average ($36.67) and 40.76% above its 200-day moving average ($34.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RAPP overbought or oversold?
At the September 3, 2026 close, RAPP's RSI(14) was 55.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $436.1M in cash and $10.1M in debt, RAPP maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$56.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -40.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing RAPP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.